Academic Journal
أعرض في EDS

Cyclosporin A Reverses Chemoresistance in Patients With Gynecologic Malignancies

التفاصيل البيبلوغرافية
العنوان: Cyclosporin A Reverses Chemoresistance in Patients With Gynecologic Malignancies
المؤلفون: Anil K. Sood, Joel I. Sorosky, Robert C. Squatrito, Jeffrey S. Skilling, Barrie Anderson, Richard E. Buller
المصدر: Neoplasia: An International Journal for Oncology Research, Vol 1, Iss 2, Pp 118-122 (1999)
بيانات النشر: Elsevier, 1999.
سنة النشر: 1999
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: multidrug resistance, cyclosporine, resistance modulation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Multidrug resistance is a major obstacle in successful systemic therapy of gynecologic malignancies. The objectives of this study are to evaluate the activity of cyclosporin A used to overcome drug resistance in a variety of gynecologic malignancies. Forty women (29 with ovarian cancer, 7 with uterine cancer, 3 with cervical cancer, and 1 with choriocarcinoma) were treated with cyclosporin A, 4 mg/kg intravenously, 6 hours before and 18 hours after the specific chemotherapeutic agent, to which the tumor had developed drug resistance. All patients had shown resistance to the chemotherapy agent used in combination with cyclosporin A. All patients had been heavily pretreated (mean, 2.8 previous chemotherapy regimens). Overall, among 38 available patients with gynecologic malignancies, a 29% objective response rate was observed. Twenty-six (65%) of all patients received three or more cycles of cyclosporin A. There was a 25% response rate for patients with ovarian cancer patients and 50% for those with uterine cancer. There were no responses among the three patients with cervical cancer, and the patient with choriocarcinoma had a complete response. All patients were evaluable for toxicity. Leukopenia and nausea were the most common toxic reactions, but in most cases they were transient, and only three patients required a treatment delay. The most common grade 3 or 4 toxicity was thrombocytopenia, which was observed in 22% of the patients. Cyclosporin A is well tolerated and has significant potential for reversal of chemoresistance in heavily pretreated patients with ovarian and uterine malignancies.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1476-5586
1522-8002
79881009
Relation: http://www.sciencedirect.com/science/article/pii/S1476558699800517; https://doaj.org/toc/1476-5586; https://doaj.org/toc/1522-8002
DOI: 10.1038/sj.neo.7900019
URL الوصول: https://doaj.org/article/edd9241e7dd84f79881009a6fc9b3f46
رقم الانضمام: edsdoj.9241e7dd84f79881009a6fc9b3f46
قاعدة البيانات: Directory of Open Access Journals
ResultId 1
Header edsdoj
Directory of Open Access Journals
edsdoj.9241e7dd84f79881009a6fc9b3f46
852
3
Academic Journal
academicJournal
851.760864257813
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.9241e7dd84f79881009a6fc9b3f46&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://doaj.org/article/edd9241e7dd84f79881009a6fc9b3f46 [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=14765586&ISBN=&volume=1&issue=2&date=19990601&spage=118&pages=118-122&title=Neoplasia: An International Journal for Oncology Research&atitle=Cyclosporin%20A%20Reverses%20Chemoresistance%20in%20Patients%20With%20Gynecologic%20Malignancies&id=DOI:10.1038/sj.neo.7900019 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Cyclosporin A Reverses Chemoresistance in Patients With Gynecologic Malignancies )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Anil+K%2E+Sood%22">Anil K. Sood</searchLink><br /><searchLink fieldCode="AR" term="%22Joel+I%2E+Sorosky%22">Joel I. Sorosky</searchLink><br /><searchLink fieldCode="AR" term="%22Robert+C%2E+Squatrito%22">Robert C. Squatrito</searchLink><br /><searchLink fieldCode="AR" term="%22Jeffrey+S%2E+Skilling%22">Jeffrey S. Skilling</searchLink><br /><searchLink fieldCode="AR" term="%22Barrie+Anderson%22">Barrie Anderson</searchLink><br /><searchLink fieldCode="AR" term="%22Richard+E%2E+Buller%22">Richard E. Buller</searchLink> )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Neoplasia: An International Journal for Oncology Research, Vol 1, Iss 2, Pp 118-122 (1999) )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Elsevier, 1999. )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 1999 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22multidrug+resistance%22">multidrug resistance</searchLink><br /><searchLink fieldCode="DE" term="%22cyclosporine%22">cyclosporine</searchLink><br /><searchLink fieldCode="DE" term="%22resistance+modulation%22">resistance modulation</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Multidrug resistance is a major obstacle in successful systemic therapy of gynecologic malignancies. The objectives of this study are to evaluate the activity of cyclosporin A used to overcome drug resistance in a variety of gynecologic malignancies. Forty women (29 with ovarian cancer, 7 with uterine cancer, 3 with cervical cancer, and 1 with choriocarcinoma) were treated with cyclosporin A, 4 mg/kg intravenously, 6 hours before and 18 hours after the specific chemotherapeutic agent, to which the tumor had developed drug resistance. All patients had shown resistance to the chemotherapy agent used in combination with cyclosporin A. All patients had been heavily pretreated (mean, 2.8 previous chemotherapy regimens). Overall, among 38 available patients with gynecologic malignancies, a 29% objective response rate was observed. Twenty-six (65%) of all patients received three or more cycles of cyclosporin A. There was a 25% response rate for patients with ovarian cancer patients and 50% for those with uterine cancer. There were no responses among the three patients with cervical cancer, and the patient with choriocarcinoma had a complete response. All patients were evaluable for toxicity. Leukopenia and nausea were the most common toxic reactions, but in most cases they were transient, and only three patients required a treatment delay. The most common grade 3 or 4 toxicity was thrombocytopenia, which was observed in 22% of the patients. Cyclosporin A is well tolerated and has significant potential for reversal of chemoresistance in heavily pretreated patients with ovarian and uterine malignancies. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article )
Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1476-5586<br />1522-8002<br />79881009 )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => http://www.sciencedirect.com/science/article/pii/S1476558699800517; https://doaj.org/toc/1476-5586; https://doaj.org/toc/1522-8002 )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1038/sj.neo.7900019 )
Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/edd9241e7dd84f79881009a6fc9b3f46" linkWindow="_blank">https://doaj.org/article/edd9241e7dd84f79881009a6fc9b3f46</link> )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.9241e7dd84f79881009a6fc9b3f46 )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1038/sj.neo.7900019 ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 5 [StartPage] => 118 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => multidrug resistance [Type] => general ) [1] => Array ( [SubjectFull] => cyclosporine [Type] => general ) [2] => Array ( [SubjectFull] => resistance modulation [Type] => general ) [3] => Array ( [SubjectFull] => Neoplasms. Tumors. Oncology. Including cancer and carcinogens [Type] => general ) [4] => Array ( [SubjectFull] => RC254-282 [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Cyclosporin A Reverses Chemoresistance in Patients With Gynecologic Malignancies [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Anil K. Sood ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Joel I. Sorosky ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Robert C. Squatrito ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jeffrey S. Skilling ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Barrie Anderson ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Richard E. Buller ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 06 [Type] => published [Y] => 1999 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 14765586 ) [1] => Array ( [Type] => issn-print [Value] => 15228002 ) [2] => Array ( [Type] => issn-print [Value] => 79881009 ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 1 ) [1] => Array ( [Type] => issue [Value] => 2 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Neoplasia: An International Journal for Oncology Research [Type] => main ) ) ) ) ) ) )
IllustrationInfo